The FDA has accepted the application for lurbinectedin in combination with atezolizumab as first-line maintenance for ES-SCLC.

The FDA granted priority review to the combination of lurbinectedin and atezolizumab as a first-line maintenance therapy for ...

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Atezolizumab may improve upon perioperative treatment with trastuzumab and chemotherapy in HER2+, locally advanced, resectable gastric or GEJ cancer, researchers say.

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

Adding atezolizumab to standard adjuvant chemotherapy significantly delayed recurrence or death for individuals with stage ...

About 15% of colon cancers are dMMR, which confers resistance to chemotherapy. ICIs have FDA approval for metastatic dMMR ...

Stephen V. Liu, MD, discusses the phase 3 IMforte study of lurbinectedin and atezolizumab in extended-stage small cell lung cancer.

Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell lung cancer (ES-SCLC) live longer versus maintenance therapy with ...

Lurbinectedin and atezolizumab performed better than atezolizumab alone as maintenance therapy for extensive-stage small cell lung cancer.